Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A phase 2 trial found that adding indoximod to temozolomide triggered meaningful immune activation in over half of recurrent ependymoma patients. Those with stronger immune responses lived nearly twice as long as those with weaker ones. The findings suggest immune activity could be a key predictor of survival in this hard-to-treat brain tumor.
A phase 2 trial (NCT04049669) evaluating the oral IDO pathway inhibitor indoximod combined with temozolomide in patients with recurrent ependymoma is showing promising early results. Presented at the 2026 SNO Annual Meeting, interim data from 54 ependymoma patients revealed an estimated median overall survival (OS) of 23.8 months — a notable benchmark for a tumor type with limited treatment options.
Using a novel combination of single-cell T-cell receptor and RNA sequencing, researchers developed a "clonal expansion index" (CEI) to measure immune responses in patients' blood. More than half of patients showed immune activation with clonal expansion of highly active T cells, primed to kill tumor cells — a signal that the IDO-blocking mechanism may be working as intended.
By the Numbers
Why it matters: Recurrent ependymoma has few effective therapies, and identifying immune biomarkers like the CEI could help clinicians predict which patients will benefit most from chemo-immunotherapy — paving the way for more personalized treatment strategies.